Events

Retiro De Equipo (Recall) de Absorb Bioresorbable Vascular Scaffold (BVS) System

Según Department of Health, Therapeutic Goods Administration, este evento ( retiro de equipo (recall) ) involucró a un dispositivo médico en Australia que fue producido por Abbott Vascular Division of Abbott Australasia Pty Ltd.

¿Qué es esto?

Una corrección al equipo o acción de retiro tomada por el fabricante para abordar un problema con un dispositivo médico. Los retiros (recalls) ocurren cuando un dispositivo médico está defectuoso, cuando puede poner en riesgo la salud, o cuando simultáneamente está defectuoso y puede poner en riesgo la salud.

Más información acerca de la data acá
  • Tipo de evento
    Recall
  • ID del evento
    RC-2017-RN-00517-1
  • Clase de Riesgo del Evento
    Class I
  • Fecha de inicio del evento
    2017-04-21
  • País del evento
    Australia
  • Fuente del evento
    DHTGA
  • URL de la fuente del evento
    https://apps.tga.gov.au/Prod/sara/arn-detail.aspx?k=RC-2017-RN-00517-1
  • Notas / Alertas
    Australian data is current through July 2018. All of the data comes from the Australian Therapeutic Goods Administration, except for the categories Manufacturer Parent Company and Product Classification.
    The Parent Company and the Product Classification were added by ICIJ.
    The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Australia.
  • Notas adicionales en la data
  • Causa
    Abbott vascular advises that, effective immediately, the absorb bioresorbable vascular scaffold (bvs) system will only be available for use in clinical registry and special access settings. data from recent analyses have demonstrated that optimal implantation technique is critical to achieving good clinical outcomes. limiting use of this device to select hospitals/institutions will enable abbott to collect additional data and monitor implantation techniques. in light of recent concerns over elevated rate of major adverse cardiac events, specifically, myocardial infarction and scaffold thrombosis, abbott vascular awaits further data to confirm whether improved implantation techniques will mitigate these higher event rates.
  • Acción
    Abbott Vascular has removed the product from the ARTG and is recalling all stock from the market until further notice. For further information please see https://www.tga.gov.au/alert/absorb-bioresorbable-vascular-scaffold-system .

Device

Absorb Bioresorbable Vascular Scaffold (BVS) System

Manufacturer

Abbott Vascular Division of Abbott Australasia Pty Ltd
  • Empresa matriz del fabricante (2017)
    Abbott Laboratories
  • Comentario del fabricante
    “We are in constant communication with regulatory agencies and competent authorities worldwide which allows us to implement global recalls or in-country communication quickly and effectively,” Abbott, which now owns St. Jude Medical told ICIJ in a statement. In addition to sending global notices to physicians worldwide, we also make sure that product advisories are available online and classification of product recalls and product advisories are determined by global regulatory bodies which can impact the timing in any given country. MD companies follow varying regulations in different countries. In come countries software is not regulated so a recall in one country related to software would not be classified as a recall or field action in another. In addition, review cycles within the regulatory process can be different in each country which can impact communication and recall timing.
  • Source
    DHTGA